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Aim To describe and interpret prostate cancer incidence 
and mortality trends in Croatia between 1988 and 2008.
Methods Incidence data for the period 1988-2008 were 
obtained from the Croatian National Cancer Registry. The 
number of prostate cancer deaths was obtained from the 
World  Health  Organization  mortality  database.  We  also 
used population estimates for Croatia from the Popula-
tion Division of the Department of Economic and Social 
Affairs of the United Nations. Age standardized incidence 
and mortality rates were calculated by the direct standard-
ization method. To describe time trends of incidence and 
mortality, joinpoint regression analysis was used.
Results  Average  age-standardized  incidence  rate  be-
tween  the  first  and  last  five-year  period  doubled,  from 
19.0/100 000 in 1988-1992 to 39.1 per 100 000 in 2004-
2008. Age-standardized mortality rate increased by 6.9%, 
from 14.5 to 15.5 per 100 000. Joinpoint analysis of inci-
dence identified two joinpoints. The increasing incidence 
trend started from 1997, with the estimated annual per-
cent of change (EAPC) of 12.9% from 1997-2002 and of 
4.1% from 2002-2008. Joinpoint analyses of mortality iden-
tified one joinpoint. Mortality trend first decreased, with 
EAPC of -3.0% from 1988-1995 to increase later with EAPC 
of 2.0% from 1995-2008.
Conclusion The incidence of prostate cancer in Croatia 
has been on the increase since 1997. Trend in mortality is 
increasing, contrary to the trends in some higher-income 
countries. An improvement in the availability of different 
treatment modalities as well as establishing prostate can-
cer units could have a positive impact on prostate cancer 
mortality in Croatia.
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Prostate cancer has become the most common male can-
cer in Western populations and the third most common 
cause of cancer death in Europe (1). In Croatia, it is the third 
most common male cancer after lung and colorectal can-
cer. In 2008, 1692 men were diagnosed with prostate can-
cer and 641 men had prostate cancer certified as cause of 
death (2,3).
There are three well-established risk factors for prostate 
cancer: increasing age, ethnic origin, and heredity (4). Oth-
er factors have also been discussed, such as nutrition, pat-
tern of sexual behavior, alcohol consumption, exposure to 
UV radiation, and occupational exposure (5).
So far, primary prevention of prostate cancer has not been 
possible, but there are means for secondary prevention. 
Prostate-specific  antigen  (PSA)  testing  was  introduced 
more than 20 years ago (6) and ever since has had a great 
impact on early prostate cancer detection. However, the 
existing evidence from meta-analyses of randomized con-
trolled trials does not support the routine use of screening 
for prostate cancer with PSA (7). In Croatia, PSA testing is 
applied as a mode of opportunistic screening, defined as 
individual case findings, which are initiated by the patient 
and/or his physician.
Prostate cancer presents significant burden for society and 
with the aging of population its incidence is expected to 
rise further. The aim of this study is to describe and inter-
pret prostate cancer incidence and mortality trends in Cro-
atia between 1988 and 2008 and to compare the current 
trends to other European countries and propose potential 




Incidence data were obtained from the Croatian National 
Cancer Registry. The Registry, founded in 1959, covers the 
whole Croatian population (approximately 4.4 million per-
sons) and relies on mandatory cancer notifications from 
primary and secondary health care sources and death cer-
tificates from the Croatian Bureau of Statistics. The Regis-
try has contributed data to the last three volumes of the 
Cancer Incidence in Five Continents series (8-10). Pros-
tate cancer was defined as ICD-10 C61 and ICD-9 185. 
The number of prostate cancer deaths was obtained 
from the WHO mortality database (11). For calculat-
ing age-specific rates for 5-year age groups, we used the 
population estimates from the Population Division of the 
Department of Economic and Social Affairs of the United 
Nations (12).
statistical analysis
Age-standardized rates of cancer incidence in Croatia and 
truncated age standardized rates (at ages 35-64) were cal-
culated by the direct standardization method, using the 
world standard population as a reference (13). To describe 
incidence and mortality time trends, we carried out join-
point regression analysis using the software Joinpoint Re-
gression Program, Version 3.5.2. October 2011. The analysis 
included logarithmic transformation of the rates, standard 
error, maximum number of five joinpoints, and minimum 
of four years between two joinpoints. All other program 
parameters were set to default values. The aim of the ap-
proach is to identify possible joinpoints where a significant 
change in the trend occurs. The method identifies join-
points based on regression models with 0-5 joinpoints. 
The final model selected was the most parsimonious of 
these, with the estimated annual percent change (EAPC) 
based on the trend within each segment (14). To quantify 
the trend over a fixed number of years, the average annual 
percent change (AAPC) was calculated. The AAPC is com-
puted as a geometric weighted average of the EAPC trend 
analysis, with the weights equal to the lengths of each seg-
ment during the prespecified fixed interval (15).
In describing trends, the terms “significant increase” or “sig-
nificant decrease” signify that the slope of the trend was sta-
tistically significant (P < 0.05). For non-statistically significant 
trends (P > 0.05), we used the terms “stable” (for EAPC be-
tween -0.5% and 0.5%), “non-statistically significant increase” 
(for EAPC>0.5%), and “non-statistically significant decrease” 
(for EAPC<-0.5%). All statistical tests were two sided.
resulTs
Age-standardized  incidence  rate  between  the  first  and 
last five years increased by 105.8%, from 19.0 to 39.1 per 
100 000, while age standardized mortality rate increased 
by just 6.9%, from 14.5 to 15.5 per 100 000 (Table 1). Inci-
dence trend exhibited significant increase (Figure 1). Join-
point analysis identified two joinpoints, in 1997 and 2002, 
with consequent three trends (Table 2). The period 1988-
1997 was characterized by a non-significant decrease, with 
EAPC of -0.8% (95% confidence interval [CI], -2.4% to 0.8%). 
The second and third period showed significantly increas-111 Kuliš et al: Prostate cancer epidemiology in Croatia
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ing trends, with EAPC of 12.9% (95% CI, 8.0% to 18%) and 
4.1% (95% CI, 2.2% to 6%), respectively. The trend since 
1997 was significantly increasing, with AAPC 8.0% (95% CI, 
5.8% to 10.2%).
Joinpoint analyses of mortality identified one joinpoint at 
the year 1995, with two trends (Table 2). In the first peri-
od, the mortality trend showed a non-significant decrease, 
with EAPC of -3.0% (95% CI, -4.9% to -1.1%), while in the 
second period it significantly increased, with EAPC of 2.0% 
(95% CI, 1.3% to 2.7%). The overall trend was stable, with 
AAPC of 0.2% (95% CI, -0.5% to 1%).
Joinpoint analyses for mortality were also performed on 
age standardized mortality rates truncated to male popu-
lation 35-64 years old. In this population, the trend showed 
a non-significant decrease, with EAPC of -0.6% (95% CI, 
-1.8% to 0.6%).
dIscussIon
Compared to GLOBOCAN 2008 estimates for other Euro-
pean countries, Croatia has an intermediate incidence rate 
of prostate cancer (16). With age-standardized rate (ASR) of 
43.2/100 000, it ranked 25th of 40 European countries. The 
highest ASR, of 126.3/100 000, was found in Ireland and the 
lowest, of 12.5/100 000, in Moldova. According to mortal-
ity, Croatia ranked 9th, with ASR of 15.4/100 000. The high-
est rate, of 22.0/100 000 was found in Estonia and the low-
est, of 6.6/100 000, in Moldova.
All European countries and the US have experienced an 
increase  in  prostate  cancer  incidence  (17,18). The  most 
prominent increase in the US occurred in the early 1990s, 
with a peak in 1992 as a result of a larger-scale PSA testing 
(18). Similar increases are described in some other Euro-
pean countries with the change of trend in the following 
years: Denmark in 1995, EAPC 7.2%; Finland in 1990, EAPC 
FIgure 1. Joinpoint analysis for incidence and mortality of prostate cancer 
in croatia, 1988-2008. rhomb – incidence; triangle – mortality; Asr  (W)– 
age-standardized rate per 100 000 (using world standard population).
TAble 1. Prostate cancer incidence and mortality in croatia in 
the period of 1988 to 2008. number of cases, crude rate, and age 
standardized rate per 100 000 (using world standard population)
Incidence Mortality
Year n crude rate Asr* n crude rate Asr
1988   558 25.7 20.6 407 18.7 14.6
1989   533 24.5 19.7 413 19.0 15.1
1990   492 22.5 17.4 398 18.2 14.2
1991   513 23.3 18.3 411 18.7 14.4
1992   560 25.3 19.2 410 18.5 14.0
1993   610 27.3 20.2 417 18.7 13.8
1994   615 27.4 19.4 426 19.0 13.5
1995.   631 28.0 18.2 354 15.7 10.7
1996   618 27.6 18.2 432 19.3 12.9
1997   613 27.5 17.7 441 19.8 12.8
1998   688 31.2 19.8 474 21.5 13.9
1999   882 40.3 25.0 463 21.2 13.2
2000   923 42.5 25.5 466 21.5 13.1
2001 1110 51.4 30.5 478 22.1 13.6
2002 1211 56.3 32.4 488 22.7 13.0
2003 1357 63.2 35.9 601 28.0 15.8
2004 1316 61.4 34.5 591 27.6 15.4
2005 1498 70.1 38.7 636 29.7 16.0
2006 1515 71.0 39.2 604 28.3 15.4
2007 1580 74.2 39.9 637 29.9 15.5
2008 1692 79.6 43.2 641 30.1 15.4
*Asr – age-standardized rate
TAble 2. Joinpoint analyses of incidence and mortality of prostate cancer with the estimated annual percent change (eAPc) and 95% 
confidence interval (cI)
Trend 1 Trend 2 Trend 3
years eAPc* 95% cI years eAPc 95% cI years eAPc 95% cI
Incidence 1988-1997 -0.8 -2.4 to 0.8 1997-2002 12.9* 8.9 to 18.0 2002-2008 4.1* 2.2 to 6.0
Mortality 1988-1995 -3.0* -4.9 to -1.1 1995-2008   2.0* 1.3 to 2.7
*significant eAPc.CANCER EPIDEMIOLOGY  112 Croat Med J. 2012;53:109-14
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9.3%; Latvia in 1994, EAPC 11.0%; Lithuania in 1991, EAPC 
8.1%; Norway in 1988, EAPC 4.0%; Sweden in 1996, EAPC 
6.9%; and the Czech Republic in 1990, EAPC 6.9% (17). In 
Croatia, prostate cancer incidence was stable from 1988 
to 1997. The increase was noted in the period after 1997, 
when the incidence increased, with EAPC of 12.9%. This in-
crease could be attributed to a wider acceptance of PSA 
testing (19), improved prostate biopsy techniques (20), and 
increased awareness of prostate cancer in Croatian male 
population.
Prostate cancer has become the most common non-skin 
cancer in European men (1). The increase in its incidence 
was influenced by increased public awareness, PSA test-
ing, and higher detection of latent cancer in prostate sur-
gery (21-24). Prostate cancer is very common in older men 
and autopsy data show that more than 50% of men older 
than 70 years have indolent prostate cancer (25-27). Fur-
thermore, it is characterized by slow growth and there is a 
common saying that most men die with the disease, not 
from it. However, prostate cancer patients have a higher 
risk of dying from various other causes (28). Even for men 
with aggressive disease there is a time lag between diag-
nosis and death. Currently, we cannot predict which lesion 
will progress and which will stay indolent (29). Since PSA 
testing has a considerable effect on increase in prostate 
cancer incidence (30), there is a large debate over poten-
tial overdiagnosis of prostate cancer (18,31). The European 
Randomized Study of Screening for Prostate Cancer during 
a median follow-up of nine years reported that PSA-based 
screening reduced the rate of death from prostate cancer 
by 20% (32). Yet, this came with a considerable risk of over-
diagnosis (defined as the diagnosis in men who would 
not have clinical symptoms during their lifetime), mean-
ing that 1410 men would need to be screened and 48 ad-
ditional cases would need to be treated to prevent one 
death from prostate cancer. Furthermore, for one man to 
experience a presumed benefit, more than 20 would have 
to be diagnosed (18). Additionally, Bray et al reported that 
in the recent years in some European countries the corre-
lation between incidence and mortality has disappeared, 
which is consistent with the overdiagnosis or detection 
of indolent tumors, most likely attributable to PSA testing. 
The highest incidence rates are reported in the countries 
with high health care expenditure, which also supports 
this notion (17).
Mortality trend in the overall period appears stable, how-
ever, joinpoint analysis identified a significant increase 
in mortality since 1995, with EAPC of 2%. Increase 
in mortality could be attributed to a potential role of in-
creased diagnosis and certification of latent prostate can-
cer in older age patients – mainly following the increase 
in PSA testing. To exclude this, we performed joinpoint 
analyses of age-standardized mortality rates truncated to 
the population 35-64 years old. Here, joinpoint identified a 
non-significant decrease, with EAPC of -0.6%.
However, in 15 of 24 European countries, there was a de-
crease in mortality despite the increase in incidence (33). It 
remains unclear whether the observed decreases in mor-
tality are associated with advancement in treatment and/
or wider level of PSA testing (17,18,34). It is also unclear to 
what extent the increases in mortality in other countries 
are the result of an increased detection of latent cases or 
of a true change in risk. However, it must be noted that the 
decreases in mortality are mostly present in higher income 
countries, ie, countries with high health care expenditures 
(eg, Germany, the UK, France, Norway) (33).
Clinical management of prostate cancer has advanced sig-
nificantly over the last two decades. Earlier cancer diagno-
sis, as a result of wider use of opportunistic PSA testing, 
has resulted in more frequent surgical treatment (ie, radi-
cal prostatectomy), especially in younger men. New treat-
ment modalities have emerged, such as brachytherapy, 
hormonal therapy, and modern radiotherapy techniques 
(eg, three-dimensional conformal radiotherapy and inten-
sity-modulated  radiotherapy)  (35).  For  locally  advanced 
disease,  combination  of  different  modality  treatments 
with long term hormonal therapy, as well as a second-line 
treatment in case of recurrence, has become an accepted 
mode of treatment. Availability and accessibility of differ-
ent modern treatment modalities has definitely had a sig-
nificant influence on mortality decline.
Treatment  of  prostate  cancer  requires  multidisciplinary 
approach. Therefore, in Europe there is an incentive to or-
ganize prostate cancer units (36). These units would be 
responsible  for  diagnosis,  staging,  and  management  of 
prostate cancer patients. It is expected that they will pro-
vide  holistic,  multiprofessional  management  of  the  dis-
ease and potentially avoid inappropriate treatments and 
secondary therapies (36).
The incidence of prostate cancer in Croatia has been on a 
continuous increase since 1997 and has not plateaued so 
far. The mortality trend is increasing, contrary to the trends 
in some higher-income countries. It remains unclear to 
what extent the increase in mortality is a result of improved 113 Kuliš et al: Prostate cancer epidemiology in Croatia
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diagnosis  and  certification  of  prostate  cancer.  However, 
improving the availability of different treatment modalities 
and establishing prostate cancer units could have a posi-
tive impact measured as a decrease in mortality.
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